<!DOCTYPE html>
<html lang="en">
    <head>
        <meta name="DC.IDENTIFIER" content="http://dx.doi.org/10.17917/PJNB-JJ95" scheme="DCTERMS.UI"><title>caNanoLab DOI Landing page</title>
        <style>
            h1 { text-align: center;}
            h2 { text-align: left;}
            table { border: 1px solid #dddddd; text-align: left; padding: 8px }
            td, th { border: 1px solid #dddddd; text-align: left; padding: 8px }
            tr:nth-child(even) { background-color: #dddddd }
        </style>
    </head><body><img src="./assets/images/crdc-logo.svg" alt="CRDC General Commons Logo"><h1> caNanoLab DOI </h1><hr><p><b>Protocol Type:</b> in vitro assay</p><p><b>Protocol Name:</b> NCL Method ITA-6.1: Leukocyte Proliferation Assay (Immunostimulation and Immunosuppression)</p><p><b>Protocol Abbreviation:</b> ITA-6.1</p><p><b>Protocol Version:</b> 4.2<hr><p><b>DOI:</b> <a href = http://dx.doi.org/10.17917/PJNB-JJ95>http://dx.doi.org/10.17917/PJNB-JJ95</a></p><p><b>Protocol File:</b> protocols/20241210_18-36-04-662_NCL_Method_ITA-6.1.pdf<p><b>File Title:</b> ITA-6.1</p><p><b>Description:</b></b> This document describes a protocol for assessing the effect of a nanoparticle formulation on the basic immunologic function of human lymphocytes, i.e. measurement of lymphocyte proliferative responses. Lymphocytes are isolated from human blood anti-coagulated with Li-heparin using Ficoll-Paque Premium solution. The isolated cells are incubated with or without phytohemaglutinin (PHA-M) in the presence or absence of nanoparticles and analyzed spectrophotometrically via the MTT (3-(4, 5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) assay.<hr><p><b>Resource Type:</b>  Protocol</p><p><b>Data Access:</b> <a href =https://general.datacommons.cancer.gov/#/data>https://general.datacommons.cancer.gov/#/data</a><p></body></html>